Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients

Journal of Infectious Diseases

Volumn 179, Issue SUPPL. 1, 1999, Pages

  Mupapa, K ^a,b,c   Massamba, M ^a,b,c   Kibadi, K ^a,b,c   Kuvula, K ^a,b,c   Bwaka, A ^a,b,c   Kipasa, M ^a,b,c   Colebunders, R ^a,b,c   Muyembe Tamfum, J J ^a,b,c  

^a Kinshasa University   (Democratic Republic Congo)

^b National Institute for Biomedical Research   (Democratic Republic Congo)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; VIRUS ANTIBODY;

ADOLESCENT; ADULT; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL FEATURE; CONFERENCE PAPER; EBOLA VIRUS; FATALITY; FEMALE; HUMAN; PALLIATIVE THERAPY; PRIORITY JOURNAL; VIRUS HEMORRHAGIC FEVER;

EID: 0033062193     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514298     Document Type: Conference Paper

References (19)

1. 1. Muyembe T, Kipasa M. Ebola haemorrhagic fever in Kikwit, Zaire [letter]. Lancet 1995;345:1448.
2. 2. Khan AS, Tshioko FK, Heymann DL, et al. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. J Infect Dis 1999; 179(suppl 1):S76-86.
3. 3. World Health Organisation. Outbreak of Ebola haemorrhagic fever in Gabon officially declared over. Wkly Epidemiol Rec 1996;17:125-6.
4. 4. Le Guenno B, Formenty P, Wyers M, Gounon P, Walker F, Boesch C. Isolation and partial characterisation of a new strain of Ebola virus. Lancet 1995;345:1271-4.
5. 5. Fisher-Hoch SP, Platt GS, Lloyd G, Simpson DIH, Neild GH, Barrett AJ. Haematological and biochemical monitoring of Ebola infection in Rhesus monkeys: implications for patient management. Lancet 1983;2: 1055-8.
6. 6. Piot P, Sureau P, Breman G, et al. Clinical aspects of Ebola virus infection in Yambuku area, Zaire, 1976. In: Pattyn SR, ed. Ebola virus haemorrhagic fever. Amsterdam: Elsevier/North-Holland, 1978:7-14.
7. 7. Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum anti-viral drug. Rev Infect Dis 1989;4(suppl 4):S750-S61.
8. 8. Fisher-Hoch SP, Khan JA, Rehman S, Mirza S, Khurshid M, McCormick JB. Crimean Congo-haemorrhagic fever treated with oral ribavirin. Lancet 1995;346:472-4.
9. 9. Emond RTD, Evans B, Bowen ETW, Lloyd G. A case of Ebola virus infection. Br Med J 1977;2:541-4.
10. 10. Ksiazek TG, Rollin PE, Williams AJ, et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1905. J Infect Dis 1999;179(suppl 1);S177-87.
11. 11. Fisher-Hoch SP. Filoviruses. In: Zuckerman AJ, Banatvala JE, Pattison JR, ed. Principles and practice of clinical virology. West Sussex, UK: Wiley & Sons, 1995:575-94.
12. 12. Hatz C, Widmer A. Un cas de virose à Ebola en Suisse. Bull Off Féd Santé Publique 1995;24:22-3.
13. 13. Isaacson M, Surreau P, Courteille G, Pattyn SR. Clinical aspects of Ebola virus disease at the Ngaliema Hospital, Kinshasa, Zaire, 1976. In: Pattyn SR. Ebola virus haemorrhagic fever. Ebola virus infection. Amsterdam: Elsevier/North-Holland, 1978:15-20.
14. 14. Baron RC, Mc Cormick JB, Tubeir OA. Ebola virus disease in Southern Sudan: hospital dissemination and intrafamilial spread. Bull World Health Organ 1983;61:997-1003.
15. 15. Rodriguez LL, De Roo A, Guimard Y, et al. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999; 179(suppl 1): S170-6.
16. 16. Georges-Courbot MC, Sanchez A, Chang-yong Lu, et al. Isolation and phylogenetic characterization of Ebola viruses causing different outbreaks in Gabon. Emerg Infect Dis 1997;1:59-62.
17. 17. Breman JG, van der Groen G, Peters CJ, Heymann DL. International colloquium on ebola virus research: summary report. J Infect Dis 1997; 176:1058-63.
18. 18. Sergeev AN, Lub MI, P'iankova OG, Kotliarov LA. The efficacy of the emergency prophylactic and therapeutic actions of immunomodulators in experimental filovirus infections. Antibiot Khimioter 1995;40:24-7.
19. 19. Jahrling PB. Passive immunisation for treatment and prophylaxis against Ebola virus infections. In: Programme and abstracts of the International Colloquium on Ebola virus research (1996, Antwerp). Antwerp: Institute of Tropical Medicine, 1996:77.